The Targeting Ageing with Metformin (tame) trial will see if metformin helps prevent cardiovascular disease, cancer and cognitive decline; it will also test the hypothesis that it reduces all-cause mortality.
It's important to understand however that all of this is new research and that these products are not interchangeable with that being said, one of these products is metformin, an FDA-approved drug that treats type 2 diabetes.
A study published in 2014 showed that diabetes patients treated with metformin enjoyed a decreased mortality rate, not just compared with patients who were not treated with it, but also with healthy controls who were not given the drug.
Metformin, marketed under the tradename Glucophage among others, is the first-line medication for the treatment of type 2 diabetes. This is particularly true in people who are overweight. It is also used in the treatment of polycystic ovary syndrome. Limited evidence suggests metformin may prevent the cardiovascular disease and cancer complications of diabetes. It is not associated with weight gain. It is taken by mouth.